2:52 PM
 | 
Feb 13, 2018
 |  BC Extra  |  Company News

FDA approves second generic of thrice-weekly Copaxone

The Sandoz Ltd. unit of Novartis AG (NYSE:NVS; SIX:NOVN) and partner Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said FDA approved an ANDA for thrice-weekly 40 mg/mL Glatopa glatiramer acetate injection as a generic version of multiple sclerosis drug Copaxone from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA).

Novartis and Momenta confirmed Sandoz has launched 40 mg/mL Glatopa, but Novartis spokesperson...

Read the full 267 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >